Skip to main content
. 2011 May 14;49(1):42–49. doi: 10.3164/jcbn.10-139

Fig. 3.

Fig. 3

TNFα and MIP-2 mRNA and 8-OHdG in liver of mice treated with copper and PPARβ/δ agonist (GW0742) or antagonist (GSK0660). (A) TNFα was upregulated in all experimental groups; in mice treated with copper it increased to 2.72 fold and to 1.85 fold in the group treated with copper and GW0742, significantly lower than copper alone group. The group treated with copper and GSK0660 experienced a steep upregulation of TNFα, 7.64 fold, significantly higher than in the group treated with copper only. (*p<0.05 vs control; †p<0.05 vs copper) (B) MIP-2 expression increased to 10.71 fold in mice treated with copper, increase that was reduced to 5.99 fold in mice treated with copper and GW0742 and steeply increased to 54.51 fold in those treated with copper and GSK0660. (*p<0.05 vs control; †p<0.05 vs copper) (C) 8-OHdG was assessed in liver DNA; mice treated with copper had almost double 8-OHdG than control (8.95 vs 17.25 pg/µg of DNA). Copper-induced increase of 8-OHdG was reduced by half in mice also treated with GW0742. GSK0660 alone and in combination with copper significantly increased 8-OHdG 3 and 2 fold respectively. Error bars represent SEM and p value was assessed by Mann-Whitney-Wilcoxon U Test (*p<0.05, **p<0.005 vs control; †p<0.05 vs copper).